Drugs
Research conducted at Yale and the Royal Women's Hospital has discovered that phenoxodiol, an investigational anticancer drug, can restore platinum drug sensitivity to some patients who have become resistant to platinum-based chemotherapy. This breakthrough has significant implications for the treatment of ovarian cancer, which is the gynecologic cancer
Drugs
Amgen has completed the Biologic License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) for panitumumab, a potential indication for the treatment of metastatic colorectal cancer in patients who have failed prior chemotherapy. The rolling BLA submission was initiated in December 2005, and the company'
Drugs
ChemGenex Pharmaceuticals has been granted orphan drug status for its most advanced drug, Ceflatonin, by the U.S. Food & Drug Administration (FDA) and the European Union for the treatment of chronic myeloid leukemia (CML). This designation provides ChemGenex with market exclusivity, protocol assistance, and reduced fees for the development
Drugs
Researchers at Hannover Medical School in Germany have successfully used the alpha-particle emitter At-211 to effectively eradicate cancer in a mouse model of genetically modified sodium/iodide symporter (NIS)-expressing tumors. By exploiting the NIS gene, the team was able to deliver the radioactive At-211 directly to the tumor cells,
Cancer treatment
Research conducted at Kyoto University Hospital in Japan has provided insights into the regulation of peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. The study focused on the human gastric cancer cell line MKN45, which expresses and functions PEPT1. The researchers found that treatment with 5-fluorouracil significantly
Cancer treatment
Infinity Pharmaceuticals, Inc. has initiated a second phase 1 clinical trial of IPI-504, a heat shock protein 90 (Hsp90) inhibitor and lead investigational anticancer agent. The open-label, dose-escalation trial will evaluate the safety, pharmacokinetic profile, and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec
Drugs
Researchers in the United States have made significant advancements in cancer therapy using targeted agents, as outlined in three studies published in various medical journals. These studies explore the efficacy and tolerability of combining bevacizumab and erlotinib, the antitumor activity of HER-2 inhibitors, and the antiangiogenic properties of cetuximab. The
Drugs
Recent research from Japan, the United States, and Italy has made significant progress in the development of anti-angiogenic therapies for cancer. These studies have highlighted the potential of targeting vascular endothelial growth factor (VEGF) receptors to inhibit tumor growth and metastasis. In Japan, researchers at Taisho Pharmaceutical Co. Ltd. have
Cancer treatment
Callisto Pharmaceuticals, Inc. has released a corporate video showcasing its lead anti-cancer drug candidates, Atiprimod and Annamycin. The video, featuring CEO Dr. Gary S. Jacob, explains the company's drug development programs and highlights the anticipated medical and marketplace advantages of its two drug candidates. Atiprimod and Annamycin are
Cancer treatment
Bayer Pharmaceuticals Corp. has submitted a Marketing Authorization Application to the European Medicines Agency for the approval of sorafenib in the treatment of advanced Renal Cell Carcinoma, also known as kidney cancer. This application is part of the companies' efforts to make the anti-cancer drug candidate available to doctors
Biotechnology industries
Bionomics Limited, an Australian-based biotechnology company, has taken a significant step in advancing its proprietary cancer drug target, BNO69, by filing further patent applications in key markets, including the United States. Building on recent scientific breakthroughs, BNO69 has emerged as a promising target for inhibiting angiogenesis, a key factor in
Biotechnology industries
Alchemia chairman Mel Bridges announced a major milestone for the company with the decision to proceed with the lead anticancer compound, ACL16907, to human clinical trials. This development marks the first compound discovered using the company's novel drug discovery technology to advance to clinical candidate status. Alchemia CEO
